Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004464 · ClinicalTrials.gov registry record · Phase 2
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
A Phase 2 study of Aplastic Anemia and Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT00004464: Completed Phase 2 study of Aplastic Anemia and Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00004464 is a Phase 2 study of Aplastic Anemia and Paroxysmal Hemoglobinuria, Nocturnal that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 69 participants, above the 40-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004464, a Phase 2 study of Aplastic Anemia and Paroxysmal Hemoglobinuria, Nocturnal, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose cyclophosphamide in patients with severe aplastic anemia. II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide shortens the time to recovery in these patients. III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal hemoglobinuria.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG filgrastim
Study Locations (1)
Maryland
- Johns Hopkins Oncology Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 1996-02 |
| Est. Completion | 2008-11-11 |
| Phase | Phase 2 |
What the finished NCT00004464 record still lists
NCT00004464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 40-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (73% higher).
The record links to 2 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00004464 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00004464 about?
NCT00004464 is a clinical study titled "Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria". OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose cyclophosphamide in patients with severe aplastic anemia. II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide shortens the time to recovery in these patients. III. Determine whether...
What is the current status of trial NCT00004464?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 1996-02. Estimated completion is 2008-11-11.
What conditions does trial NCT00004464 study?
This clinical trial studies the following conditions: Aplastic Anemia, Paroxysmal Hemoglobinuria, Nocturnal.
What interventions are being tested in trial NCT00004464?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (DRUG).
Who is sponsoring clinical trial NCT00004464?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004464 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004464's enrollment target sits among peer trials
69 4th of 23 higher than 20 of 23 other Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
A Study of Emapalumab for Pediatric Aplastic Anemia
RECRUITING · Phase 2
-
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
RECRUITING · Phase 2
-
Haploidentical HCT for Severe Aplastic Anemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia